Type 2 Diabetes
Conditions
Keywords
anthocyanin, blaeberries, bilberries, blueberries, mirtoselect, type 2 diabetes, insulin resistance, Adipose tissue, inflammation
Brief summary
Dietary strategies for alleviating the metabolic complications such as diabetes associated with obesity are actively being pursued as alternatives to pharmaceutical interventions The genus Vaccinium (e.g. blueberry, blaeberry, cranberry) has been used traditionally as a source of folk remedies for established diabetic symptoms, primarily as leaf or stem infusions or decoctions. Berries from this family such as blaeberry (BL) and blueberry (BB) are enriched in anthocyanins, polyphenolics recognized for their ability to provide and activate cellular antioxidant protection, inhibit inflammatory gene expression, and consequently protect against oxidant-induced and inflammatory cell damage and cytotoxicity. The association of obesity with adipose tissue stress, macrophage recruitment, and inflammatory gene expression suggests that eating edible berries from this genus might provide an effective alternative or supplementary intervention to attenuate obesity- associated inflammation and the associated insulin resistance. The aim of this study is to determine the effects of anthocyanin supplementation in the form of a concentrated blaeberry extract on insulin resistance and inflammation particularly in the adipose tissue following a three week supplementation period.
Interventions
DIETARY_SUPPLEMENTMirtoselect
Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance. Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days.
Sponsors
University of Aberdeen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Obese male subjects (BMI \> 30) * Aged \> 40 and \< 70 years of age * Type 2 diabetes; subjects controlling their diabetes by diet alone or with impaired glucose tolerance * All the obese subjects will have a waist circumference over 40 inches * All subjects must live the Aberdeenshire area of Scotland
Exclusion criteria
Medical
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oral Glucose Tolerance Test | Day 0 and 21 days post intervention | Change in Oral Glucose Tolerance following intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting blood glucose/insulin | Day 0, 7, 14, and 21 days post intervention | Change in fasting blood glucose/insulin in response to intervention |
Countries
United Kingdom
Outcome results
None listed